Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,770 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overuse of imaging in prostate cancer staging.
Tohi Y, Kato T, Kohashiguchi K, Kaji A, Fujiwara K, Harada S, Abe Y, Naito H, Okazoe H, Taoka R, Ueda N, Sugimoto M. Tohi Y, et al. Among authors: kato t. Int J Urol. 2025 Feb 3. doi: 10.1111/iju.70003. Online ahead of print. Int J Urol. 2025. PMID: 39900439
Validation of five prognostic models treated with axitinib beyond first-line nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma: a Japanese multicenter retrospective study.
Kikuchi H, Osawa T, Matsushita Y, Kojima T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Ueda K, Tanaka H, Kurahashi T, Bando Y, Kimura T, Nishiyama N, Kato T, Hara H, Ito Y, Kitamura H, Miyake H, Shinohara N. Kikuchi H, et al. Among authors: kato t. Jpn J Clin Oncol. 2025 Feb 2:hyaf018. doi: 10.1093/jjco/hyaf018. Online ahead of print. Jpn J Clin Oncol. 2025. PMID: 39893579
Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC.
Tohi Y, Kobayashi K, Daizumoto K, Sekino Y, Fukuhara H, Niigawa H, Katayama S, Shimizu R, Takamoto A, Nishimura K, Nagami T, Hayashida Y, Hirama H, Shiraishi K, Tomida R, Kobatake K, Inoue K, Miyaji Y, Bekku K, Morizane S, Miura N, Wada K, Sugimoto M; Chu-shikoku Japan Urological Consortium. Tohi Y, et al. Jpn J Clin Oncol. 2025 Feb 2:hyaf025. doi: 10.1093/jjco/hyaf025. Online ahead of print. Jpn J Clin Oncol. 2025. PMID: 39893578
Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases.
Yamamichi G, Kato T, Yoshimura A, Tani M, Horibe Y, Liu Y, Sassi N, Okuda Y, Oka T, Uemura T, Yamamoto A, Ishizuya YU, Hayashi T, Yamamoto Y, Hatano K, Kawashima A, Takao T, Nishimura K, Takada S, Tsujihata M, Nonomura N. Yamamichi G, et al. Among authors: kato t. Anticancer Res. 2025 Feb;45(2):639-650. doi: 10.21873/anticanres.17451. Anticancer Res. 2025. PMID: 39890197
Prognostic values of proteinuria in patients with acute heart failure.
Akama Y, Matsue Y, Maeda D, Dotare T, Sunayama T, Iso T, Fujimoto Y, Nakade T, Yatsu S, Ishiwata S, Nakamura Y, Suda S, Kato T, Hiki M, Kasai T, Minamino T. Akama Y, et al. Among authors: kato t. J Cardiol. 2025 Jan 28:S0914-5087(25)00010-3. doi: 10.1016/j.jjcc.2025.01.010. Online ahead of print. J Cardiol. 2025. PMID: 39884428
12,770 results
You have reached the last available page of results. Please see the User Guide for more information.